Document Detail

Pregabalin for the treatment of fibromyalgia.
MedLine Citation:
PMID:  22725707     Owner:  NLM     Status:  MEDLINE    
INTRODUCTION: Fibromyalgia (FM) is the most common cause of chronic widespread body pain in humans. Co-morbidities include sleep disturbance, fatigue, impaired physical functioning, altered mood and negative effects on health-related quality of life. Pregabalin inhibits presynaptic release of pronociceptive neurotransmitters in the CNS; this likely underpins its therapeutic benefit in patients with FM.
AREAS COVERED: This review addresses pregabalin pharmacokinetics, efficacy and adverse event (AE) profiles from randomized controlled trials and open-label extension studies in patients with FM. These effects are compared with those of the serotonin norepinephrine reuptake inhibitors, duloxetine and milnacipran that also have FDA approval for the treatment of fibromyalgia.
EXPERT OPINION: At the approved dosages, oral pregabalin has at most a moderate therapeutic benefit above placebo with tolerable side-effects, in no more than 50% of patients with FM. Durability of clinically meaningful (≥ 30%) pain relief in pregabalin-responders has been demonstrated for at least 6-months, but longer-term studies are required as most patients have symptoms for decades. Exclusion of patients with common co-morbidities from the pregabalin RCTs in FM raises questions on the generalizability of the RCT findings to the typical patient seen in clinical practice and so additional investigation is required.
Maree T Smith; Brendan J Moore
Related Documents :
20543997 - Imitate: an intensive computer-based treatment for aphasia based on action observation ...
22273247 - Using qualitative research to inform the development of a comprehensive outcomes assess...
22742447 - World assumptions, posttraumatic stress and quality of life after a natural disaster: a...
22839747 - The association between online gaming, social phobia, and depression: an internet survey.
12851087 - Impairment level sumscore for lower extremity complex regional pain syndrome type i.
3168937 - Iopamidol as contrast medium in endoscopic retrograde pancreatography: a prospective ra...
Publication Detail:
Type:  Comparative Study; Journal Article; Review    
Journal Detail:
Title:  Expert opinion on pharmacotherapy     Volume:  13     ISSN:  1744-7666     ISO Abbreviation:  Expert Opin Pharmacother     Publication Date:  2012 Jul 
Date Detail:
Created Date:  2012-06-25     Completed Date:  2012-11-20     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  100897346     Medline TA:  Expert Opin Pharmacother     Country:  England    
Other Details:
Languages:  eng     Pagination:  1527-33     Citation Subset:  IM    
Centre for Integrated Preclinical Drug Development & Professor of Pharmacy, The University of Queensland, Steele Building, St Lucia Campus, Brisbane, Queensland, 4072, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Analgesics / pharmacology,  therapeutic use*
Fibromyalgia / drug therapy*
Serotonin Uptake Inhibitors / therapeutic use
gamma-Aminobutyric Acid / analogs & derivatives*,  pharmacology,  therapeutic use
Reg. No./Substance:
0/Analgesics; 0/Serotonin Uptake Inhibitors; 55JG375S6M/pregabalin; 56-12-2/gamma-Aminobutyric Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Position of indapamide, a diuretic with vasorelaxant activities, in antihypertensive therapy.
Next Document:  Promiscuous mating in the harem-roosting fruit bat, Cynopterus sphinx.